Skip to content
Menu

Stifel Maintains Buy on Arrowhead Pharma, Lowers Price Target to $96

Benzinga Newsdesk 3 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.

Stifel analyst James Condulis maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price target from $104 to $96.

Read at benzinga.com